merck kgaa springworks - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Bloomberg on MSN · 5h

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Reuters on MSN · 3h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Investopedia on MSN · 10h

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.

Merck's Strategic $3.9 Billion Move: A Boon for Rare Cancer Therapies

Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...

15h

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Merck puts a price on its SpringWorks takeover bid

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results